Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba
|
|
- Cecil Hunter
- 6 years ago
- Views:
Transcription
1 Original papers Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba Sarah Elsabagh Psychopharmacology Research Unit, Centre for Neuroscience, King s College London, London and Centre for Pharmacognosy and Phytotherapy, The School of Pharmacy, London, UK. David E. Hartley Psychopharmacology Research Unit, Centre for Neuroscience, King s College London, London, UK. Sandra E. File Psychopharmacology Research Unit, Centre for Neuroscience, King s College London, London, UK. Journal of Psychopharmacology 19(2) (2005) British Association for Psychopharmacology ISSN SAGE Publications Ltd, London, Thousand Oaks, CA and New Delhi / Abstract Gingko biloba has cognitive benefits both in populations suffering from dementia and after acute treatment in healthy volunteers, with some evidence indicating that those with poorer cognitive performance show greater benefit. We have previously found that 1 week of treatment with ginkgo improved attention, memory and mental flexibility in postmenopausal women, but the evidence for any beneficial effects of longer treatment is less well-established. The present study aimed to determine whether cognitive benefits, similar to those previously found after 1 week of treatment, would persist after 6 weeks of treatment, and whether those with poorer cognitive performance would benefit more. In a placebo-controlled, double-blind study, postmenopausal women (aged years) were randomly allocated to receive a standardized extract of ginkgo (LI 1370, Lichtwer Pharma, Marlow, UK) (one capsule/day of 120 mg, n = 45) or matching placebo (n = 42) for 6 weeks. According to an established reproductive staging system, subjects were divided into those in the early (Stage +1; mean age 55 years) and late (Stage +2: mean age 61 years) stages of menopause. At baseline and after 6 weeks of treatment, subjects completed tests of mental flexibility, planning, memory and sustained attention, and ratings of mood, sleepiness, bodily and menopausal symptoms. The only significant effects of ginkgo were in the test of mental flexibility, in which there were significant menopausal stage ginkgo interactions. This was because subjects in Stage +2 required fewer trials to complete the task and made fewer errors after ginkgo treatment, whereas those in Stage +1 showed no benefits. Subjects in Stage +2 had poorer performance at baseline compared to those in Stage +1 both in this task and the test of planning ability. The beneficial effects of ginkgo were limited to the test of mental flexibility and to those with poorer performance. Keywords attention, frontal lobe function, Ginkgo biloba, memory, mental flexibility, mood, planning, postmenopausal women Introduction Extracts from the leaves of the Ginkgo biloba tree have been used therapeutically in the Far East for millennia in the treatment of a wide variety of ailments. More recently, the beneficial effects of ginkgo in the treatment of cognitive disorders have received attention in the West, and its efficacy in the treatment of Alzheimer s disease and vascular dementia is reasonably well-established (Kanowski et al., 1996; Le Bars et al., 1997; Oken et al., 1998; Birks et al., 2002). There is also evidence that acute administration of ginkgo can improve cognition in healthy individuals. In young volunteers, acute doses ( mg) improved performance on factors measuring memory and attention and in serial subtraction, which has components of working memory and attention (Kennedy et al., 2000, 2002; Scholey and Kennedy, 2002). In a slightly older healthy group (30 59 years), ginkgo (120 mg) improved shortterm memory (Rigney et al., 1999), with a greater improvement demonstrated in the oldest group (50 59 years). There is also some evidence that benefits may persist after short-term, sub-chronic, treatment. Moulton et al. (2001) demonstrated some improvement in male college students on the Sternberg memory test after 5 days of ginkgo treatment (120 mg/day), and Hartley et al. (2003) found that postmenopausal women performed better than the placebo group in tests of attention, short-term memory and mental flexibility after 7 days of ginkgo treatment (120 mg/day). Stough et al. (2001) found improved performance with ginkgo (120 mg/day) after 30 days of treatment in healthy subjects (aged years) in digit span backwards, working memory speed, and an auditory verbal learning test. In addition, the group with lower cognitive ability improved on Trails A. However, in older groups, Corresponding author: Sarah Elsabagh, Psychopharmacology Research Unit, Centre for Neuroscience, Hodgkin Building, King s College London, Guy s Campus, London SE1 1UL, UK. sarah.elsabagh@kcl.ac.uk
2 174 Limited cognitive benefits of treatment with Ginkgo biloba the evidence for positive effects after chronic treatment is less convincing. Cieza et al. (2003) found no improvement on tests of attention or memory after 4 weeks of treatment in healthy middleaged volunteers (50 65 years). In elderly volunteers after 6 weeks of ginkgo treatment, Mix and Crews (2000, 2002) found limited evidence of improvement, and Solomon et al. (2002) found no effect on 15 measures of memory. Persson et al. (2004) selected subjects (aged years) who had regularly taken ginkgo supplements for 2 years and found no effects on any of the eight tests of episodic and semantic memory compared to a control group. There are several explanations for any lack of effect in the older groups after chronic treatment. One is the possibility that older people are unable to benefit from ginkgo. This would appear to be unlikely because Rigney et al. (1999) found greater improvement in the group of older subjects, Hartley et al. (2003) found improved performance in post-menopausal women and benefits have also been found in dementia patients (Kanowski et al., 1996; Oken et al., 1998). The second possibility is that the age-range and range of cognitive performance in some of the studies was too wide for potential benefits to be identified. It is possible that the benefits of ginkgo are more marked in those subjects who have lower levels of performance. The results of two studies indicate that ginkgo might have greater cognitive benefits in sub-groups with poorer cognitive performance (Rigney et al., 1999; Stough et al., 2001). Gessner et al. (1985) found that only a sub-group with a more impaired electroencephalogam (EEG) profile at baseline showed improvements in vigilance and quicker reaction times after 12 weeks of treatment with ginkgo. The contention that older subjects may benefit to a greater extent than younger subjects is supported by an animal study showing that 3 weeks of ginkgo treatment (100 mg/kg/day) improved passive avoidance learning solely in an aged group of mice (Stoll et al., 1996). The third possible explanation for a relative lack of effects after chronic treatment is that tolerance develops with longer periods of treatment. The aim of the present study was to investigate the effects of 6 weeks of treatment with ginkgo in a group of postmenopausal women of similar age-range to those previously studied. The same battery of tests was selected as was previously used by Hartley et al. (2003) to determine whether the cognitive benefits found in that study would persist after a longer period of treatment. The same dose of gingko (120 mg/day) was also selected because this is the dose at which cognitive benefits have most frequently been reported, as well as being the lower dosage-range prescribed for the chronic treatment of dementia and intermittent claudication in Germany (Upton, 2003). The benefits of ginkgo on cognition, although slight, have been previously demonstrated by 6 weeks (Mix and Crews, 2000, 2002). A secondary aim of the study was to determine whether any benefits would be more marked in those individuals with greater cognitive impairment. To investigate this, we divided our group on the basis of the time after menopause, according to a classified system of reproductive ageing (Soules et al., 2001). In Stage +1, oestrogen levels are declining, whereas they have reached a steady low level in in Stage +2. Thus, women within 5 years after menopause (Stage +1) were compared with those > 5 years after menopause (Stage +2). Materials and methods Participants Ninety-six healthy, postmenopausal women aged years were recruited by circular at King s College London or by advertisements in the local press. King s College Ethical Committee approved the study and volunteers provided their written informed consent. Volunteers were defined as postmenopausal if they had not menstruated within the previous 12 months. Exclusion criteria included current illness, use of hormone replacement theapy (currently or within the previous 12 months), use of psychoactive or anti-coagulant medication, use of ginkgo, ginseng or isoflavone supplements or estimated verbal IQ scores < 90. They were randomly allocated to the ginkgo or placebo-treatment groups. Nine subjects (six in the placebo group and three in the ginkgo group) dropped out during the course of the study for various personal reasons, but none reported any side-effects. Nine subjects had hysterectomies (five in the ginkgo group and four in the placebo group), and one subject in the ginkgo group had a hysterectomy and oophorectomy. Five subjects were smokers: four in the ginkgo group (smoking a mean of nine cigarettes/day) and one subject in the placebo group (smoking 12 cigarettes/day). The subjects in each treatment group were stratified into those in Stage +1 (early stage) of the menopause ( 5 years after the final menstrual period; n = 25 in the placebo group, n = 18 in the ginkgo group) and those in Stage +2 (late stage, > 5 years after the final menstrual period; n = 17 in the placebo group, n = 27 in the ginkgo group) according to the guidelines of the stages of reproductive aging workshop (Soules et al., 2001). For those subjects who had hysterectomies before reaching menopause, the stage of menopause was calculated using the mean of the group age at menopause (51 years) as a guideline. One subject who had undergone a hysterectomy and oophorectomy had a natural menopause before the surgical procedure and was in Stage +2. Supplement administration The ginkgo biloba supplement used was Ginkyo One-A-Day tablets (supplied by Lichtwer Pharma UK, Marlow, UK), which contains the standardized extract LI 1370 obtained from the green leaves of the Ginkgo biloba tree. This extract comprises 25% ginkgo flavonoids and 6% terpenoids. The placebo tablets were identical in appearance (also supplied by Lichtwer). Subjects received one tablet containing 120 mg ginkgo biloba extract or the identical placebo tablet each morning for 6 weeks. Subjects were instructed to take their last tablet on the morning of the 6-week test session. Compliance was monitored by placing seven extra tablets in each bottle and asking subjects to return their tablet bottles at the end of treatment so that the remaining tablets could be counted. The administration was double-blind and neither subjects nor experimenters were aware of the treatment groups.
3 Limited cognitive benefits of treatment with Ginkgo biloba 175 Procedure The subjects were required to attend two test sessions at the Psychopharmacology Research Unit, King s College London. The baseline test session was before the start of treatment and the second session was after 6 weeks of treatment. Subjects were tested 4 5 h after their last dose on the 6-week test session. This coincides with the time at which peak activity levels of ginkgo are reached (Upton, 2003), and at which positive effects on memory have been reported after a single dose (Kennedy et al., 2000). At the baseline test session, subjects were given a practice session to familiarize themselves with the computerized test battery. An estimate of verbal IQ was obtained using the National Adult Reading Test Revised version (NART-R) (Nelson and Willison, 1991). Thereafter the battery of tests was identical at both sessions. Measures of menopausal symptoms, anxiety and depression The Hospital Anxiety and Depression Scale (HAD) (Zigmond and Snaith, 1983) was used to determine levels of trait anxiety and depression. Menopausal symptoms were assessed by the Greene Climacteric Scale (Greene, 1998), from which four independent measures can be extracted: psychological, somatic, vasomotor symptoms and sexual dysfunction. Visual Analogue Scales Before and after cognitive testing, subjects were asked to complete Visual Analogue Scales to assess current mood state (Bond and Lader, 1974) and bodily symptoms of somatic anxiety (Tyrer, 1976). Each scale consisted of two items separated by a 100-mm vertical line. Subjects were instructed to place a perpendicular mark at the appropriate place on each line to indicate how they were feeling at that time. The current state of sleepiness was measured by the Stanford Sleepiness Scale (Hoddes et al., 1973), which was administered before and after the test session. The Epworth Sleepiness Scale (Johns, 1991, 1992) was administered after the test session and measured how sleepy the subjects usually feel. Cognitive tests Sustained attention The Paced Auditory Serial Addition Task (PASAT) was used to assess sustained attention (Spreen and Strauss, 1991). This task involves adding together successive pairs of digits read from a list of 61 numbers. There were four presentation speeds, with digits presented every 2.4, 2.0, 1.6 and 1.2 s. The first two presentation speeds were used as a practice and the two fastest presentation speeds were used to assess performance. The number of correct responses was recorded as a score out of 60 for the two fastest presentation speeds. Episodic memory There were three tests of episodic memory. In the immediate and delayed paragraph recall test (from the Weschler Memory Scale-Revised; Weschler, 1987), 25 units of information were read at the rate of 1 unit per second, and subjects were instructed to remember the paragraph as accurately as possible. They were asked for their recall immediately after hearing the story and after a delay of 30 min. The number of correctly remembered units was scored. The Delayed Matching-to-Sample (DMTS) task was from the Cambridge Neuropsychological Test Automated Battery (CANTAB CeNeS, Cambridge) and was used to assess short-term, non-verbal memory. In this test, subjects were presented with a sample pattern which they were instructed to remember. The sample pattern and three distracter patterns then appeared either simultaneously or after a delay of 0, 4 or 12 s, and the subject had to select the sample pattern that they had just been presented with. The total number of correct responses and the latency to respond were recorded. Long-term episodic memory was assessed using a picture recall task. Subjects were presented with 20 pictures of common objects for 5 s per picture, and were then asked to recall as many items as they could remember after a 25 min delay. Category generation Subjects were asked to name all the animals they could think of that belonged to a particular category (house, farm or jungle). They were given 20 s for each category. A total score was derived from all admissible answers for each category. Planning ability The Stockings of Cambridge (SoC) task is a spatial planning test from the CANTAB, based on the Tower of London task (Shallice, 1982) and is described in detail by Owen et al. (1990). Subjects were presented with an arrangement of coloured balls housed in stockings that had to be rearranged in the fewest moves possible to match a goal arrangement presented at the top of the screen. The task varied in difficulty from two to five moves. The two- and three-move problems were used for practice and the four- and five-move problems were recorded. The number of moves for each task and the subsequent thinking time were recorded Mental flexibility The Intra/Extra Dimensional Shift (IDED) task from the CANTAB involves rule learning, shifting and reversal and is a measure of mental flexibility controlled by the frontal cortex (Owen et al., 1991). In the first stage, subjects were required to learn a simple discrimination. Once the rule was correctly learned, it was then reversed or shifted. The number of trials taken and the number of errors made to reach the Extra-Dimensional Shift (EDS) stage were recorded. Statistical analysis To determine whether treatment had differential effects in subjects depending on their menopausal stage, the data for the cognitive test measures were analysed using three-way analysis of variance (ANOVA). The between group factors were treatment group and menopausal stage, and the repeated measures factor was week. The three mood factors and Stanford Sleepiness Scales were analysed by four-way ANOVA, with treatment and menopausal stage as the between-group factors and repeated measures factors of time (before and after cognitive testing) and week. A four-way multivariate analysis (MANOVA) was used to analyse the factor of
4 176 Limited cognitive benefits of treatment with Ginkgo biloba somatic anxiety derived from the Bodily Symptoms Scale. Where this reached significance, data for the individual items were subsequently analysed by ANOVA. Where effects reached significance, both F-ratios and probability levels are quoted. Where results did not reach significance, only the F-ratios are presented and nonsignificance indicated (NS). Data were analysed using SPSS for Windows (version 10.1; SPSS Inc., Chicago, IL, USA). Results Subject characteristics The groups did not differ on predicted verbal IQ scores, body mass index, years of secondary education, typical alcohol consumption, daily caffeine consumption, or anxiety and depression ratings on the HAD Scales (treatment, menopausal stage and treatment menopausal stage interaction, F < 3.3, NS in all cases). As expected, the subjects in Stage +2 of menopause were significantly older than those in Stage +1 [F(1,83) = 71.7, p < ] (Table 1). At baseline, the subjects in Stage +1 of menopause had significantly higher ratings of vasomotor symptoms than those in Stage +2 [F(1,83) = 8.5, p < 0.005], but there were no differences in ratings of psychological symptoms or sexual dysfunction (F < 2.0, NS in all cases), or sleepiness as measured by the Epworth or Stanford Scales (Tables 2 and 3) (F < 2.0, NS in all cases). Menopausal symptoms and HAD Scales Ginkgo was without effect on menopausal symptoms or anxiety and depression as measured on the HAD Scales (week treatment and week treatment menopausal stage interactions, F < 2.5, NS in all cases). However, there was a significant effect of week for psychological symptoms [F(1,83) = 14.3, p < ], ratings of sexual dysfunction [F(1,75) = 11.5, p < 0.001] on the Greene Climacteric Scale, and anxiety ratings on the HAD A Scale [F(1,83) = 6.2, p < 0.02] because all subjects improved after 6 weeks of treatment. There was a significant week menopausal stage interaction for ratings of somatic menopausal symptoms [F(1,83) = 4.3, p < 0.05] because of improvement for the subjects in Stage +1 (Table 2). Table 1 Age, predicted verbal IQ (based on the National Adult Reading Test), years of secondary education, body mass index, daily consumption of caffeinated drinks (cups), weekly alcohol consumption (units), and scores on the Hospital Anxiety and Depression Scales (HAD A and HAD D ) of the subjects allocated to placebo and ginkgo groups in Stage +1 and Stage +2 of the menopause Stage + 1 Stage + 2 Placebo Ginkgo Placebo Ginkgo Age (years)* 55.5 ± ± ± ± 0.7 IQ ± ± ± ± 1.7 Years of secondary education 5.6 ± ± ± ± 0.3 Body mass index 25.4 ± ± ± ± 0.5 Daily caffeinated drinks (cups) 4.4 ± ± ± ± 0.7 Weekly alcohol intake (units) 5.1 ± ± ± ± 1.0 HAD A 5.5 ± ± ± ± 0.5 HAD D 3.0 ± ± ± ± 0.4 Data are mean ± SEM. *p < Stage +1 verses Stage +2. Table 2 Scores for Hospital Anxiety and Depression Scales (HAD A and HAD D ), psychological, somatic, vasomotor symptoms and sexual dysfunction on the Greene Climacteric Scale and sleepiness assessed by the Epworth Scale at baseline and after 6 weeks of treatment with placebo or ginkgo for subjects in Stage +1 and Stage +2 of the menopause Stage +1 Stage +2 Placebo Ginkgo Placebo Ginkgo Baseline Week 6 Baseline Week 6 Baseline Week 6 Baseline Week 6 HAD A * 5.5 ± ± ± ± ± ± ± ± 0.6 HAD D 3.0 ± ± ± ± ± ± ± ± 0.5 Greene Climacteric Scale Psychological symptoms*** 7.0 ± ± ± ± ± ± ± ± 0.7 Somatic symptoms 2.2 ± ± ± ± ± ± ± ± 0.6 Vasomotor symptoms 2.2 ± ± ± ± ± ± ± ± 0.4 Sexual dysfunction*** 1.1 ± ± ± ± ± ± ± ± 0.2 Epworth Sleepiness Scale 6.0 ± ± ± ± ± ± ± ± 0.8 Data are mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001, baseline week 6 changes in all groups. p < 0.05, Stage +1 group.
5 Limited cognitive benefits of treatment with Ginkgo biloba 177 Table 3 Scores for the three mood factors extracted from the Bond and Lader (1974) mood rating scale and on the Stanford Sleepiness Scale, before (Pre) and after (Post) cognitive testing at baseline and after week 6 of treatment with placebo or ginkgo, for subjects in Stage +1 or Stage +2 of the menopause Placebo Ginkgo Baseline Week 6 Baseline Week 6 Pre Post Pre Post Pre Post Pre Post Stage +1 Anxiety*** 44.8 ± ± ± ± ± ± ± ± 3.9 Alertness*** 47.7 ± ± ± ± ± ± ± ± 3.5 Wellbeing*** 50.8 ± ± ± ± ± ± ± ± 3.4 Stanford*** 2.1 ± ± ± ± ± ± ± ± 0.4 Stage +2 Anxiety*** 43.7 ± ± ± ± ± ± ± ± 2.3 Alertness*** 52.8 ± ± ± ± ± ± ± ± 2.0 Wellbeing*** 54.1 ± ± ± ± ± ± ± ± 3.0 Stanford *** 2.1 ± ± ± ± ± ± ± ± 0.2 Data are mean ± SEM. ***p < 0.001, Pre Post cognitive testing differences in all groups. Sleepiness and Visual Analogue Self-Rating Scales Ginkgo was without effect on self-ratings of sleepiness on the Stanford and Epworth Sleepiness Scales (week treatment and week treatment menopausal stage interactions, F < 2.3, NS in all cases) (Table 3). Three independent mood factors can be extracted from the Bond and Lader Mood Rating Scale (Bond and Lader, 1974). Ginkgo was without effect on these mood factors. There were no significant week treatment or week treatment menopausal stage interactions for any of the factors alertness, anxiety or well-being (F < 1.6, NS in all cases) (Table 3). Furthermore, there was no difference between the two treatment groups in response to the stress of cognitive testing (week treatment time and week treatment menopausal stage time, F < 3.4, NS in all cases). The Bodily Symptoms Scale provides a measure of somatic anxiety. There were no significant effects of Ginkgo on this factor, and the groups did not differ in their response to the test session (MANOVA, all treatment interactions F < 1.5, NS in all cases; data not shown). Cognitive tests Sustained attention Ginkgo was without effect on this task (all treatment interactions, F < 2.5, NS in all cases) (Table 4). However, there was a significant practice effect because all subjects improved on the second test occasion [week, F(1,69) = 28.6, p < for 1.6 s and F(1,65) = 41.9, p < for 1.2 s]. There was no effect of menopausal stage in this task (F < 1.2, NS in both cases). Episodic memory There were no significant effects of ginkgo on the episodic memory tests of immediate and delayed paragraph recall, DMTS or picture recall (treatment interactions, F < 3.2, NS in all cases) and there were no effects of menopausal stage (F < 2.4, NS in all cases) (Table 4). There was a significant effect of week on all of these tasks because all subjects improved regardless of treatment group [F(1,83) = 4.3, p < 0.05 for DMTS number correct; F(1,83) = 41.7, p < for immediate paragraph recall; F(1,83) = 19.4, p < for delayed paragraph recall; F(1,83) = 60.7, p < for picture recall]. Category generation There were no significant effects of ginkgo on the category generation task (treatment interactions, F < 1.9, NS in both cases), and there was no effect of menopausal stage (F = 0.1, NS) (Table 4). There was a significant effect of week because all subjects improved on the task regardless of treatment [F(1,83) = 13.4, p < ]. Planning There were no effects of ginkgo on the SoC task (all treatment interactions F < 2.7, NS in all cases); however, there was a significant effect of week for the subsequent thinking time [F(1,83) = 10.3, p < for the four-move problem and F(1,83) = 9.0, p < for the five-move problem] because all subjects were faster on the second test occasion (Table 4). There was a significant effect of menopausal stage in this task, because subjects in Stage +2 had worse performance than subjects in Stage +1 on the number of moves to complete the task for the five-move problem [F(1,83) = 4.1, p < 0.05]. Mental flexibility Only 75 subjects out of the total sample were able to reach the EDS stage of the task, and thus the results were analysed for these subjects only. Ginkgo significantly improved performance in this task, but only in the Stage +2 subjects. Thus, there were significant week treatment menopausal stage interactions for the number of trials to reach the EDS stage [F(1,71) = 4.5, p = 0.04] and the number of errors to reach the EDS stage [F(1,71) = 5.7, p = 0.02] (Fig. 1). However, the groups did not differ significantly on post-hoc tests. There were also significant main
6 178 Limited cognitive benefits of treatment with Ginkgo biloba Table 4 Scores on the cognitive tests at baseline and after 6 weeks of treatment with placebo or ginkgo for subjects in Stage +1 or Stage +2 of the menopause Stage + 1 Stage + 2 Placebo Ginkgo Placebo Ginkgo Baseline Week 6 Baseline Week 6 Baseline Week 6 Baseline Week 6 Picture recall (number correct)*** 9.9 ± ± ± ± ± ± ± ± 0.5 Immediate paragraph recall (items recalled)*** 14.0 ± ± ± ± ± ± ± ± 0.5 Delayed paragraph recall (items recalled)*** 12.7 ± ± ± ± ± ± ± ± 0.7 Category generation (number of items)*** 23.4 ± ± ± ± ± ± ± ± 0.9 DMTS Total number correct* 17.4 ± ± ± ± ± ± ± ± 0.3 Mean correct latency 3082 ± ± ± ± ± ± ± ± 137 PASAT 1.6 s*** 24.5 ± ± ± ± ± ± ± ± 1.8 PASAT 1.2 s*** 20.5 ± ± ± ± ± ± ± ± 1.4 Stockings of Cambridge Mean subsequent thinking time(ms) Four-move problem* 1851 ± ± ± ± ± ± ± ± 166 Five-move problem* 632 ± ± ± ± ± ± ± ± 694 Number of moves Four-move problem 5.7 ± ± ± ± ± ± ± ± 0.2 Five-move problem 6.3 ± ± ± ± ± ± ± ± 0.3 Data are mean ± SEM. *p < 0.05, **p < 0.001, ***p < 0.001, baseline-week 6 change in scores for all subjects. p < 0.05, Stage +1 verses Stage +2 scores. DMTS, Delayed Matching-to-Sample; PASAT, Paced Auditory Serial Addition Task. IDED Errors Placebo Ginkgo IDED * * Trials Number of errors to criterion Change from baseline Stage +1 Stage +2 Number of trials to criterion Change from baseline Stage +1 Stage +2 Figure 1 Mean (± SEM) change in performance from baseline to week 6, after treatment with placebo or ginkgo for subjects in Stage +1 and Stage +2 of the menopause, in the number of trials and errors to reach criterion in the Intra/Extra Dimensional Shift (IDED) task. *p < 0.05, significant week treatment menopausal stage interaction
7 Limited cognitive benefits of treatment with Ginkgo biloba 179 effects of menopausal stage in this task, because those in Stage +2 required more trials to reach the EDS stage [F(1,71) = 10.4, p < 0.003] and made more errors to reach this stage [F(1,71) = 10.0, p < 0.003]. Discussion This study has shown that, after 6 weeks of treatment with ginkgo, the only cognitive improvement was in mental flexibility, and this was limited to older subjects who had significantly poorer performance on this task at baseline. We utilized a fairly large group size, and positive effects of ginkgo have been detected in smaller group sizes (Hartley et al., 2003); thus, it is unlikely that a larger group size would have resulted in more significant effects, especially because there were no effects of ginkgo at marginal levels of significance. Because the test battery was identical to that used in the previous study, it is unlikely that an inappropriate selection of tests could have accounted for the results. After 1 week of treatment, we found that ginkgo improved sustained attention (PASAT) and short-term memory (DMTS), in addition to mental flexibility (Hartley et al., 2003). In comparing the present study with our previous study, there was no statistically significant difference in baseline scores on DMTS or PASAT; thus, it is unlikely that differences in performance between the two studies could have accounted for the lack of the effect of ginkgo on these tasks. However, the practice effects on DMTS and PASAT were greater in the present study compared to the previous study, which may have reduced the effects of ginkgo on these tasks. Alternatively, tolerance may develop to the effects of ginkgo with chronic treatment. This notion is supported by evidence that tolerance may develop to the effects of ginkgo on EEG recordings. Acute doses of ginkgo have been shown to elicit the EEG profile of a cognitive activator in healthy volunteers (Luthringer et al., 1995; Itil et al., 1996). However, after 12 weeks of treatment in subjects with ageassociated cognitive decline, there were no effects on the EEG profile, except for a subset of subjects who showed more impaired vigilance at baseline (Gessner et al., 1985). This comprises further evidence that the effects of ginkgo may depend on the target population and that, after chronic treatment, greater effects may be apparent where there is a greater degree of cognitive impairment. Importantly, mental flexibility was found to be improved in our previous study on the effects of ginkgo in postmenopausal women after 1 week of treatment (Hartley et al., 2003). In this previous study of subjects who were able to reach the ID shift stage, we found a significant effect of ginkgo in the latency to make correct responses, although further analysis of our data also showed significant effects on the number of stages completed, total trials-adjusted and total errors-adjusted (p < 0.04 in all cases), with the ginkgo group performing better. Thus, it appears that the effects of ginkgo in this task are quite robust because, after prolonged treatment, the improvement in mental flexibility is sustained. It is of particular interest that improvement was found on a test of frontal lobe function. Inhibitory functions of the frontal cortex are sensitive to the effects of ageing and this is thought to contribute to the decline in performance on other cognitive tasks involving memory and attention (Persad et al., 2002). Furthermore, Robbins et al. (1998) demonstrated that the IDED task was the most sensitive of the CANTAB tests to the effects of ageing, and found deterioration in performance of this task in the group aged years. This supports our findings of deterioration on the task between groups with a mean age difference of 6 years. We also found evidence for poorer performance on the SoC task in the group aged over 55 years. Robbins et al. (1998) also found an age-related decline in this task, but only within the oldest age group (75 79 years). Although the SoC task is also a measure of frontal lobe function, the planning aspects of the task were found to load onto a different factor from the IDED task (Robbins et al., 1998). Thus, it is unsurprising that performance on this task was not improved by ginkgo. No effect of ginkgo was found in this task in our previous study of the effects of 1 week of treatment in postmenopausal women (Hartley et al., 2003). Although there has been limited investigation into the effects of ginkgo on frontal lobe tasks, working memory, which utilizes the frontal lobes, has been improved after acute (Rigney et al., 1999) and chronic (Stough et al., 2001) treatment with ginkgo. It is difficult to conclude whether the crucial difference between our Stage +1 and Stage +2 subjects was their age or their menopausal status. During Stage +1 of the menopause, hormonal levels continue to decline, whereas they have reached a steady low level in Stage +2 (Soules et al., 2001). A recent study has identified oestrogenic activities of ginkgo. The whole extract and the flavonoid glycoside components (quercetin, kaempferol and isorhamnetin) were found to competitively bind with the oestrogen receptors (ERs) in vitro and exert weakly oestrogenic activities shown by the induction of cell proliferation through a typical ERresponse pathway (Oh and Chung, 2004). The physiological significance of these effects has not yet been determined. However, if this is an important mechanism underlying the cognitive effects of ginkgo, this effect may be of greater importance in Stage +2. In this study, all subjects reported improved menopausal symptoms and anxiety ratings after the 6 weeks of treatment, regardless of treatment group, which indicates a non-specific beneficial effect of participating in this trial. We found no effects of ginkgo on mood, in agreement with our results after 1 week of treatment (Hartley et al., 2003). Beneficial effects have been found in a similar age group with respect to self-rated mental health and quality of life (Cieza et al., 2003), but these are rather different from the mood scales used in the present study. However, a study by Cockle et al. (2000) indicated a significant improvement in ratings of activities of daily living and self-mood ratings, which assessed anxiety, depression, sedation and sleep behaviour after 1 4 months of treatment with ginkgo (120 mg/day) in an elderly group of subjects (mean age 69 years). Although the reported benefits were more pronounced for the group aged under 60 years, a limitation was that the study was not placebo-controlled, and the importance of this is highlighted by the significant placebo-effect noted in the present study. A variety of mechanisms have been proposed for the effects of ginkgo and it has been suggested that the polyvalent activity of the total extract is responsible for the overall beneficial cognitive effects (DeFeudis and Drieu, 2000). However, it is likely that after
8 180 Limited cognitive benefits of treatment with Ginkgo biloba acute/short-term treatment, only some mechanisms are able to take effect. For example, it is possible that, in healthy subjects, ginkgo may act immediately to increase cerebral blood flow and blood glucose levels (Krieglstein et al., 1986), which are related to cognitive performance (Gur et al., 1987; Benton and Owens, 1993) but, after repeated administration, tolerance may develop to these effects. However, there is evidence from a forearm blood flow study that increased flow persists for at least 6 weeks of treatment in healthy subjects (Mehlsen et al., 2002). Animal studies have shown ginkgo to increase the release of neurotransmitters such as acetylcholine (DeFeudis, 1991) and noradrenaline (Brunello et al., 1985) in the rat brain after acute or short-term treatment, although there is a down-regulation of the associated receptors after longer periods of days. This may represent an adaptive response of the brain underlying the development of tolerance to cognitive benefits after longer periods of treatment with ginkgo in healthy populations. Ginkgo has been shown to have cognitive benefits over treatment periods of up to 52 weeks in patients suffering from Alzheimer s disease, vascular dementia and cerebral insufficiency syndrome (Taillandier et al., 1986; Le Bars et al., 1997), but it is possible that there are different mechanisms underlying ginkgo s effects in patient versus healthy populations. For example, the neuroprotective effects of ginkgo, such as prevention of oxidative mitochondrial damage (Sastre et al., 1998; Spinnewyn et al., 1995) and attenuation of Aß-mediated toxicity (Bastianetto et al., 2000), are more pertinent to patient populations where oxidative damage is a major contributor to the clinical symptoms of cognitive decline. Such mechanisms may be of limited use in non-clinical populations. Our finding that improvement in mental flexibility was only sustained in the older and more cognitively impaired agegroup may indicate that there is a threshold of cognitive ability at which ginkgo is effective after chronic treatment periods. In summary, the range of benefits from ginkgo appears to be reduced after 6 weeks of treatment, although the improved mental flexibility is maintained in an older group of subjects. If a benefit is retained after longer periods of treatment, this could prove to be of very real value, particularly if the effect is more marked in older and/or more cognitively impaired individuals. Acknowledgements This work was funded by a grant from the Dunhill Medical Trust. We would like to thank Dr R. Middleton of Lichtwer Pharma UK for the generous gift of Ginkyo and matched placebo tablets and for help in recruiting volunteers. References Bastianetto S, Ramassamy C, Dore S, Christen Y, Poirier J, Quirion R (2000) The Ginkgo biloba extract (EGb 761) protects hippocampal neurons against cell death induced by beta-amyloid. Eur J Neurosci 12: Benton D, Owens D S (1993) Blood glucose and human memory. Psychopharmacology 113: Birks J, Grimley E V, Van Dongen M (2002) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 4: CD Bond A J, Lader M (1974) The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: Brunello N, Racagni G, Clostre F, Drieu K, Braquet P (1985) Effects of an extract of Ginkgo biloba on noradrenergic systems of rat cerebral cortex. Pharmacol Res Commun 17: Cieza A, Maier P, Poppel E (2003) Effects of Ginkgo biloba on mental functioning in healthy volunteers. Arch Med Res 34: Cockle S M, Kimber S, Hindmarch I (2000) The effects of Ginkgo biloba extract (LI 1370) supplementation on activities of daily living in free living older volunteers: a questionnaire survey. Hum Psychopharmacol 15: DeFeudis F V (1991) In vivo studies with EGb 761. In DeFeudis F V (ed.) Ginkgo biloba extract (EGb761): Pharmacological activities and clinical application. Elsevier, Paris, pp DeFeudis F V, Drieu K (2000) Ginkgo biloba extract (EGb 761) and CNS functions: basic studies and clinical applications Curr Drug Targets 1: Gessner B, Voelp A, Klasser M (1985) Study of the long-term action of a Ginkgo biloba extract on vigilance and mental performance as determined by means of quantitative pharmaco-eeg and psychometric measurements. Arzneimittelforschung 35: Greene J C (1998) Constructing a standard climacteric scale. Maturitas 29: Gur R C, Gur R E, Obrist W D, Skolnick B E, Reivich M (1987) Age and regional cerebral blood flow at rest and during cognitive activity. Arch Gen Psychiatry 44: Hartley D E, Heinze L, Elsabagh S, File S E (2003) Effects on cognition and mood in postmenopausal women of 1-week treatment with Ginkgo biloba. Pharmacol Biochem Behav 75: Hoddes E, Zarcone V, Smythe H, Phillips R, Dement W C (1973) Quantification of sleepiness: a new approach. Psychophysiology 10: Itil T M, Eralp E, Tsambis E, Itil K Z, Stein U (1996) Central nervous system effects of Ginkgo biloba, a plant extract. Am J Ther 3: Johns M W (1991) A new method for measuring daytime sleepiness the Epworth sleepiness. Sleep 14: Johns M W (1992) Reliability and factor-analysis of the Epworth sleepiness scale. Sleep 15: Kanowski S, Herrmann W M, Stephan K, Wierich W, Horr R (1996) Proof efficacy of the Ginkgo biloba special extract EGb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29: Kennedy D O, Scholey A B, Wesnes K A (2000) The dose-dependent cognitive effects of acute administration of Ginkgo biloba to healthy young volunteers. Psychopharmacology 151: Kennedy D O, Scholey A B, Wesnes K A (2002) Modulation of cognition and mood following administration of single doses of Ginkgo biloba, ginseng, and a ginkgo/ginseng combination to healthy young adults. Physiol Behav 75: Krieglstein J, Beck T, Seibert A (1986) Influence of an extract of Ginkgo biloba on cerebral blood flow and metabolism. Life Sci 39: Le Bars P L, Katz M M, Berman N, Itil T M, Freedman A M, Schatzberg A F (1997) A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 278: Luthringer R, d Arbigny P, Machler J P (1995) GBE-EEG event-related potential mapping profile. In Christen Y, Courtosis Y, Droy-Lefaix M T (eds), Advances in Ginkgo biloba Extract (EGb 761) on Aging and Age- Related Disorders. Elsevier, Paris, pp Mehlsen J, Drabaek H, Wiinberg N, Winther K (2002) Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging 22: Mix J A, Crews W D Jr (2000) An examination of the efficacy of Ginkgo
9 Limited cognitive benefits of treatment with Ginkgo biloba 181 biloba extract EGb761 on the neuropsychologic functioning of cognitively intact older adults. J Altern Complement Med 6: Mix J A, Crews W D Jr (2002) A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17: Moulton P L, Boyko L N, Fitzpatrick J L, Petros TV (2001) The effect of Ginkgo biloba on memory in healthy male volunteers. Physiol Behav 73: Nelson H E, Willison J R (1991) Restandardisation of the NART Against the WAIS-R. NFER-Nelson, Windsor Oh S M, Chung K H (2004) Estrogenic activities of Ginkgo biloba extracts. Life Sci 74: Oken B S, Storzbach D M, Kaye J A (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease Arch Neurol 55: Owen A M, Downes J J, Sahakian B J, Polkey C E, Robbins T W (1990) Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28: Owen A M, Roberts A C, Polkey C E, Robbins T W (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29: Persad C C, Abeles N, Zacks R T, Denburg N L (2002) Inhibitory changes after age 60 and their relationship to measures of attention and memory. J Gerontol B Psychol Sci Soc Sci 57: Persson J, Bringlov E, Nilsson L G, Nyberg L (2004) The memory-enhancing effects of Ginseng and Ginkgo biloba in healthy volunteers. Psychopharmacology 172: Rigney U, Kimber S, Hindmarch I (1999) The effects of acute doses of standardized Ginkgo biloba extract on memory and psychomotor performance in volunteers. Phytother Res 13: Robbins T W, James M, Owen A M, Sahakian B J, Lawrence A D, McInnes L, Rabbitt P M (1998) A study of performance on tests from the CANTAB battery sensitive to frontal lobe dysfunction in a large sample of normal volunteers: implications for theories of executive functioning and cognitive aging. Cambridge Neuropsychological Test Automated Battery. J Int Neuropsychol Soc 4: Sastre J, Millan A, Garcia de la Asuncion J, Pla R, Juan G, Pallardo, O Connor E, Martin J A, Droy-Lefaix M T, Vina J (1998) A Ginkgo biloba extract (EGb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Biol Med 24: Scholey A B, Kennedy D O (2002) Acute, dose-dependent cognitive effects of Ginkgo biloba, Panax ginseng and their combination in healthy young volunteers: differential interactions with cognitive demand. Hum Psychopharmacol 17: Shallice T (1982) Specific impairments of planning. Philos Trans R Soc Lond B Biol Sci 298: Solomon P R, Adams F, Silver A, Zimmer J, DeVeaux R (2002) Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288: Soules M R, Sherman S, Parrott E, Rebar R, Santoro N, Utian W, Woods N (2001) Stages of Reproductive Aging Workshop (STRAW). J Womens Health Gend Based Med 10: Spreen O, Strauss E (1991) A Compendium of Neuropsychological Tests: Administration Norms and Commentary. Oxford University Press, New York Spinnewyn B, Blavet N, Drieu K (1995) Effect of Ginkgo biloba extract (Egb 760) on oxygen consumption by isolated cerebral mitochondria. In Christen Y, Courtois Y, Droy-Lefaix MT (eds), Advances in Ginkgo biloba Extract Research, Effects of Ginkgo biloba Extract (Egb 761) on ageing and age-related disorders. Elsevier, Paris, pp Stoll S, Scheuer K, Pohl O, Muller W E (1996) Ginkgo biloba extract (EGb 761) independently improves changes in passive avoidance learning and brain membrane fluidity in the aging mouse. Pharmacopsychiatry 29: Stough C, Clarke J, Lloyd J, Nathan P J (2001) Neuropsychological changes after 30-day Ginkgo biloba administration in healthy participants. Int J Neuropsychopharmacol 4: Taillandier J, Ammar A, Rabourdin J P, Ribeyre J P, Pichon J, Niddam S, Pierart H (1986) Treatment of cerebral aging disorders with Ginkgo biloba extract. A longitudinal multicenter double-blind drug vs. placebo study. Presse Med 15: Tyrer P (1976) The Role of Bodily Feelings in Anxiety. Oxford University Press, London Upton R (2003) Ginkgo Leaf & Ginkgo Leaf Extract: Ginkgo biloba L. Standards of Analysis, Quality Control, and Therapeutics. American Herbal Pharmacopoeia, Santa Cruz, p. 24 Weschler D (1987) Weschler Memory Scale revised. Harcourt Brace Jovanovich, San Antonio, CA Zigmond A S, Snaith R P (1983) The hospital anxiety and depression scale. Acta Psychiatric Scand 67:
Differential cognitive effects of Ginkgo biloba after acute and chronic treatment in healthy young volunteers
Psychopharmacology (2005) 179: 437 446 DOI 10.1007/s00213-005-2206-6 ORIGINAL INVESTIGATION Sarah Elsabagh. David E. Hartley. Osama Ali. Elizabeth M. Williamson. Sandra E. File Differential cognitive effects
More informationCognitive function in late versus early postmenopausal stage
Maturitas 56 (2007) 84 93 Cognitive function in late versus early postmenopausal stage Sarah Elsabagh, David E. Hartley, Sandra E. File Psychopharmacology Research Unit, Centre for Neuroscience, Hodgkin
More informationBrief Report. Does Modafinil Enhance Cognitive Performance in Young Volunteers Who Are Not Sleep-Deprived?
Brief Report Does Modafinil Enhance Cognitive Performance in Young Volunteers Who Are Not Sleep-Deprived? Delia C. Randall, BSc,*y Aparna Viswanath,* Punam Bharania,* Sarah M. Elsabagh, BSc,* David E.
More informationEfficacy and safety of a Ginkgo biloba extract
Public Health Nutrition: 3(4A), 495±499 495 Efficacy and safety of a Ginkgo biloba extract PL Le Bars 1,2, * and J Kastelan 2,3 1 New York University Medical Center, New York, USA: 2 Memory Centers of
More informationIs Ginkgo biloba a cognitive enhancer in healthy individuals? A meta-analysis
human psychopharmacology Hum. Psychopharmacol Clin Exp 2012; 27: 527 533. Published online 24 September 2012 in Wiley Online Library (wileyonlinelibrary.com).2259 REVIEW ARTICLE Is Ginkgo biloba a cognitive
More informationSchizophrenia Battery
Schizophrenia Battery Cantab Schizophrenia Battery A c c e l e r a t e t h e d e v e l o p m e n t o f s a f e a n d e f f e c t i v e m e d i c i n e s Fast, reliable and highly sensitive, the Cantab
More informationDegenerative neurological disease is one of the most significant
Journal of the Australian Traditional-Medicine Society A LITERATURE REVIEW OF THE EFFICACY OF GINKGO BILOBA IN COGNITIVE DYSFUNCTION KEIR SOOBY Abstract Cognitive dysfunction and dementia are issues of
More informationTHE EFFECTS OF GINKGO BILOBA ON MEMORY, REACTION TIME, AND MOOD. Emily Katherine Qualls
THE EFFECTS OF GINKGO BILOBA ON MEMORY, REACTION TIME, AND MOOD by Emily Katherine Qualls B.A., The University of West Florida, 2004 A thesis submitted to the Department of Psychology College of Arts and
More informationCANTAB Test descriptions by function
CANTAB Test descriptions by function The 22 tests in the CANTAB battery may be divided into the following main types of task: screening tests visual memory tests executive function, working memory and
More informationTrail making test A 2,3. Memory Logical memory Story A delayed recall 4,5. Rey auditory verbal learning test (RAVLT) 2,6
NEUROLOGY/2016/790584 Table e-1: Neuropsychological test battery Cognitive domain Test Attention/processing speed Digit symbol-coding 1 Trail making test A 2,3 Memory Logical memory Story A delayed recall
More informationMemory and Cognition. Anthony Mander Lancaster House Oldham
Memory and Cognition Anthony Mander Lancaster House Oldham manderanthony@hotmail.com Three stages of memory Encoding Put in memory Storage Maintain in memory Retrieval Recover from memory Memory Short-Term
More informationHill, Elisabeth L Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), pp ISSN [Article]
Hill, Elisabeth L.. 2004. Executive dysfunction in autism. Trends in Cognitive Sciences, 8(1), pp. 26-32. ISSN 13646613 [Article] http://research.gold.ac.uk/2558/ The version presented here may differ
More informationGinkgo biloba: no robust effect on cognitive abilities or mood in healthy young or older adults
human psychopharmacology Hum Psychopharmacol Clin Exp 2006; 21: 27 37. Published online 5 December 2005 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/hup.739 Ginkgo biloba: no robust
More informationRanking Nutritional Supplements Botanical Medicine Primary
Your Monthly Update Dear Colleague Welcome to the October newsletter from Pure Bio Ltd. Did you know...? The UK organic market grew by 30% and averaged sales of 7million a week in 2005! Our topic for this
More informationTable 1: Summary of measures of cognitive fatigability operationalised in existing research.
Table 1: Summary of measures of cognitive fatigability operationalised in existing research. Candidate Mmeasures Studies Procedure Self-reported fatigue measure Key Findings The auditory As and auditory
More informationTreatment of AD with Stabilized Oral NADH: Preliminary Findings
MS # 200 000 128 Treatment of AD with Stabilized Oral NADH: Preliminary Findings G.G. Kay, PhD, V. N. Starbuck, PhD and S. L. Cohan, MD, PhD Department of Neurology, Georgetown University School of Medicine
More informationResearch Adviser : Dr. Ramon Jason Javier
A Single-Blind Randomized Controlled Trial on the Effectiveness of Gingko biloba in Increasing Immediate Memory Index Scores of Healthy UERMMMCI Medical Students Using the Repeatable Battery for the Assessment
More informationTable 1. Studies excluded from the meta-analysis on cardiovascular effects.
Table 1. Studies excluded from the meta-analysis on cardiovascular effects. Author Year Compound Duration Patients' gender Brüll V 2017 Quercetin 6 weeks Both Carmignani LO Chedraui P 2008 Chuengsam arn
More informationINTRODUCTION. ORIGINAL ARTICLE Copyright 2016 Korean Neuropsychiatric Association
ORIGINAL ARTICLE https://doi.org/10.4306/pi.2016.13.6.590 Print ISSN 1738-3684 / On-line ISSN 1976-3026 OPEN ACCESS A Comparative Study of Computerized Memory Test and The Korean version of the Consortium
More informationEarly intervention in Bipolar Disorder
Early intervention in Bipolar Disorder Lakshmi N. Yatham MBBS, FRCPC, MRCPsych Professor of Psychiatry, University of British Columbia, Vancouver, Canada Early Intervention in Bipolar Disorder High Risk
More informationThe ABCs of Dementia Diagnosis
The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What
More informationPRIMARY CARE PSYCHIATRY VOL. 9, NO. 1, 2003, 15 20
PRIMARY CARE PSYCHIATRY VOL. 9, NO. 1, 2003, 15 20 10.1185/135525703125002342 2003 LIBRAPHARM LIMITED Use of St John s wort (Hypericum perforatum L) in members of a depression self-help organisation: a
More informationΔTHC level. ΔTHC-COOH level
Supplemental information 12 2 11 18 1 16 THC (ng/dl) A 9 8 7 6 5 4 3 2 1 5 1 15 2 Minutes 25 ΔTHC level B 14 12 1 8 6 4 2-2 -4 y = 11.92x + 42.11 R² =.1375 y =.196x + 29.63 R² =.2977 y =.1513x +.8471 R²
More informationTerm Paper: Ginkgo Biloba s Influence on Memory and Cognition
1 Term Paper: Ginkgo Biloba s Influence on Memory and Cognition 2 Introduction The aging process is inevitable. Over time our bodies and the functions they provide start to decline in many aspects. Cognitive
More informationGINKGO BILOBA. Ingrid Bergman said, Happiness is good health and a bad memory. But a healthy, happy life is one worth remembering.
GINKGO BILOBA Don t forget herbal help. Enerex Ginkgo Biloba contains the potent memory-boosting standardized extract and the powdered leaf of the Ginkgo Biloba plant for maximum medicinal benefit. Ginkgo
More informationThe current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease
The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,
More informationCTIS-Adverse Effects
White Paper CTIS-Adverse Effects A new Clinical Trial Information System for assessing cognitive safety in Phase I drug trials Dr Andrew Blackwell, Chief Scientific Officer, Cambridge Cognition 2 CTIS-Adverse
More informationClinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers
Br. J. clin. Pharmac. (1988), 26, 607-611 Clinical pharmacology of sibutramine hydrochloride (BTS 54524), a new antidepressant, in healthy volunteers D. J. KING & NOELEEN DEVANEY Department of Therapeutics
More informationNature, prevalence and clinical significance. Barcelona, Spain
Nature, prevalence and clinical significance Jaime Kulisevsky Barcelona, Spain 1 Non motor (neuropsychiatric) symptoms are an integral part of Parkinson s s disease (PD) Affective disorders And are associated
More informationI Can t Think Properly Brian Fog & POTS
I Can t Think Properly Brian Fog & POTS Satish R Raj MD MSCI FACC FHRS Libin Cardiovascular Institute of Alberta University of Calgary Autonomic Dysfunction Center Vanderbilt University School of Medicine
More informationApproccio nutraceutico alla gestione del declino cognitivo iniziale
Approccio nutraceutico alla gestione del declino cognitivo iniziale Arrigo F.G. Cicero, MD, PhD Medical and Surgical Sciences Dept. Alma Mater Studiorum University of Bologna Prevalence: 5.5-7.7% over
More information1 Institute of Psychological Sciences, University of Leeds, UK 2 Department of Psychology, Harit-Watt University, Edinburgh, UK
The art of self-testing by attempting cryptic crosswords in later life: the effect of cryptic crosswords on memory self-efficacy, metacognition and memory functioning Nicholas M. Almond 1*, Catriona M.
More informationA multimodal model for the prediction of driving behavior
A multimodal model for the prediction of driving behavior Ion Beratis, MSc, PhD Psychologist-Neuropsychologist 2 nd Department of Neurology Attikon University Hospital, National University of Athens, Greece
More informationElderly Norms for the Hopkins Verbal Learning Test-Revised*
The Clinical Neuropsychologist -//-$., Vol., No., pp. - Swets & Zeitlinger Elderly Norms for the Hopkins Verbal Learning Test-Revised* Rodney D. Vanderploeg, John A. Schinka, Tatyana Jones, Brent J. Small,
More informationCompetition vs. Collaboration Test Proposal. By: Kaya, Adam, Johana, and Mike
Competition vs. Collaboration Test Proposal By: Kaya, Adam, Johana, and Mike The Overarching Question: Is there a higher rate of occurrence of neural synchrony during competition or collaboration? Our
More informationA Nutritionally Based Approach for Functional Mental Enhancement Assessment Using a Double-Blind, Placebo- Controlled, Randomized Clinical Trial
ISPUB.COM The Internet Journal of Nutrition and Wellness Volume 4 Number 1 A Nutritionally Based Approach for Functional Mental Enhancement Assessment Using a Double-Blind, Placebo- Controlled, Randomized
More informationUniversity of Wollongong. Research Online
University of Wollongong Research Online Faculty of Social Sciences - Papers Faculty of Social Sciences 211 Examining brain-cognition effects of Ginkgo Biloba extract: brain activation in the left temporal
More informationAdrafinil: A Novel Vigilance Promoting Agent
Adrafinil: A Novel Vigilance Promoting Agent Norton W. Milgram, Heather Callahan, and Christina Siwak Division of Life Sciences, University of Toronto at Scarborough, Toronto, Ontario, Canada Introduction
More informationClinical Trial Synopsis TL , NCT#
Clinical Trial Synopsis, NCT#00492011 Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Ability of Ramelteon 1 mg, 4 mg, and 8 mg to Alleviate the Insomnia
More informationPlenary Session 2 Psychometric Assessment. Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo
Plenary Session 2 Psychometric Assessment Ralph H B Benedict, PhD, ABPP-CN Professor of Neurology and Psychiatry SUNY Buffalo Reliability Validity Group Discrimination, Sensitivity Validity Association
More informationSupplementary Online Content
Supplementary Online Content Chew EY, Clemons TE, Agrón E, et al; Age-Related Eye Disease Study 2 Research Group. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on
More informationBiological Risk Factors
Biological Risk Factors Ms Angelina Crea Provisional Psychologist Academic Child Psychiatry Unit Royal Children s Hospital Professor Alasdair Vance Head Academic Child Psychiatry Department of Paediatrics
More informationAdaptive Design in CIAS
Adaptive Design in CIAS or If you don t know where you re going, any road will get you there Michael Sand, PhD, MPH Senior Clinical Program Leader, CNS Boehringer Ingelheim Disclosures I m an employee
More informationHOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?
EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of
More informationShort & Long term effects of dietary habits on Cognitive Function
School of something FACULTY OF OTHER Short & Long term effects of dietary habits on Cognitive Function Louise Dye Human Appetite Research Unit Institute of Psychological Sciences University of Leeds l.dye@leeds.ac.uk
More informationInterpreting change on the WAIS-III/WMS-III in clinical samples
Archives of Clinical Neuropsychology 16 (2001) 183±191 Interpreting change on the WAIS-III/WMS-III in clinical samples Grant L. Iverson* Department of Psychiatry, University of British Columbia, 2255 Wesbrook
More informationAssessing cognition in ELDERLY drivers
Assessing cognition in ELDERLY s Alexandra Economou Assistant Professor Department of Psychology University of Athens 18 October 2013 Athens Overview ability in the older ability in the older The older
More informationTreatment of Mood Disorders in Midlife Women
Treatment of Mood Disorders in Women KAY ROUSSOS-ROSS, MD UNIVERSITY OF FLORIDA DEPARTMENTS OF OBGYN AND PSYCHIATRY Disclosures I HAVE NO DISCLOSURES Objectives UNDERSTAND INCIDENCE OF MOOD DISORDERS IN
More informationSUPPLEMENTARY MATERIAL DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT IN PATIENTS WITH COPD AND CONTROL SUBJECTS
SUPPLEMENTARY MATERIAL DOMAIN-SPECIFIC COGNITIVE IMPAIRMENT IN PATIENTS WITH COPD AND CONTROL SUBJECTS Fiona A.H.M. Cleutjens, Frits M.E. Franssen, Martijn A. Spruit, Lowie E.G.W. Vanfleteren, Candy Gijsen,
More informationNutrients and Circulatory Function
Clinical Nutrition Research Centre Nutrients and Circulatory Function Peter Howe Clinical Nutrition Research Centre University of Newcastle Nutritional Physiology Research Centre University of South Australia
More informationClinical Study Depressive Symptom Clusters and Neuropsychological Performance in Mild Alzheimer s and Cognitively Normal Elderly
Hindawi Publishing Corporation Depression Research and Treatment Volume 2011, Article ID 396958, 6 pages doi:10.1155/2011/396958 Clinical Study Depressive Symptom Clusters and Neuropsychological Performance
More informationEffects of Sleep Deprivation on Short Duration Performance Measures Compared to the Wilkinson Auditory Vigilance Task
Sleep, 1(2): 169-176 1978 Raven Press, New York Effects of Sleep Deprivation on Short Duration Performance Measures Compared to the Wilkinson Auditory Vigilance Task Marilyn Glenville, Roger Broughton,
More informationFRONTO-STRIATAL COGNITIVE DEFICITS AT DIFFERENT STAGES OF PARKINSON'S DISEASE
Brain (1992). 115, 1727-1751 FRONTO-STRIATAL COGNITIVE DEFICITS AT DIFFERENT STAGES OF PARKINSON'S DISEASE by A. M. OWEN,' M. JAMES, 2 P. N. LEIGH, 3 B. A. SUMMERS, 3 C. D. MARSDEN, 4 N. P. QUINN, 4 K.
More informationExploration of social rule violation in patients with focal prefrontal neurosurgical lesions
Exploration of social rule violation in patients with focal prefrontal neurosurgical lesions R G Morris 1, E Pullen 2, S Kerr 3, P R Bullock 4 and R P Selway 5 1 Neuropsychology Unit, Department of Psychology,
More informationEBM Journal Club: Does Ginkgo Biloba improve memory in elder group
EBM Journal Club: Does Ginkgo Biloba improve memory in elder group R2 0 Memory loss in elder >> Dementia Defination Diagnosis Prognosis 1 Why so serious? 2 Any way to improve memory in elder??? 3 Any way
More informationPersonality and Individual Differences
Personality and Individual Differences 98 (2016) 85 90 Contents lists available at ScienceDirect Personality and Individual Differences journal homepage: www.elsevier.com/locate/paid Relations of naturally
More informationANTEROGRADE AMNESIA INDUCED BY THE HYPNOTIC DIAZEPAM IS NOT ASSOCIATED WITH SLEEPINESS
ANTEROGRADE AMNESIA INDUCED BY THE HYPNOTIC DIAZEPAM IS NOT ASSOCIATED WITH SLEEPINESS Agnieszka Unrug l, Marielle Gorissen 2, Gilles van Luijtelaar l, Anton Coenen l 1 NICI, Department of Psychology,
More informationConscious control of movements: increase of temporal precision in voluntarily delayed actions
Acta Neurobiol. Exp. 2001, 61: 175-179 Conscious control of movements: increase of temporal precision in voluntarily delayed actions El bieta Szel¹g 1, Krystyna Rymarczyk 1 and Ernst Pöppel 2 1 Department
More informationCarmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation
Carmen Inoa Vazquez, Ph.D., ABPP Clinical Professor NYU School of Medicine Lead Litigation Conference Philadelphia May 19, 2009 Presentation Neuropsychological Tests Battery The following List represents
More informationRapid communication Integrating working memory capacity and context-processing views of cognitive control
THE QUARTERLY JOURNAL OF EXPERIMENTAL PSYCHOLOGY 2011, 64 (6), 1048 1055 Rapid communication Integrating working memory capacity and context-processing views of cognitive control Thomas S. Redick and Randall
More informationPrevalence of cognitive impairment in major depression and bipolar disorder
Received: 7 September 2017 Revised: 5 November 2017 Accepted: 15 December 2017 DOI: 10.1111/bdi.12602 ORIGINAL ARTICLE Prevalence of cognitive impairment in major depression and bipolar disorder Katie
More informationAdverse effects of caffeine after a single dose and after repeated doses consumed within a day
Adverse effects of caffeine after a single dose and after repeated doses consumed within a day Anders Sjödin Copenhagen University (Denmark) Chair of EFSA s WG on caffeine EFSA STAKEHOLDERS MEETING ON
More informationNeurocognitive and psychosocial outcomes of obstructive sleep apnoea in Hong Kong Chinese
HEALTH AND HEALTH SERVICES RESEARCH FUND Neurocognitive and psychosocial outcomes of obstructive sleep apnoea in Hong Kong Chinese EYY Lau *, MSM Ip, TMC Lee K e y M e s s a g e s 1. Patients with obstructive
More informationThe Implementation of Scenar Therapy in the clinical practice of a GERONTOLOGIST.
Translation from Russian to English Language Publication: Authors: Setchenov Moscow Medical Academy and The International Scenar Academy (Moscow) A. Revenko Article name: The Implementation of Scenar Therapy
More informationManagement of a HIV-infected patient with a psychiatric disorder
Management of a HIV-infected patient with a psychiatric disorder Maria Ferrara, Modena, Italia Guida Da Ponte, Lisboa, Portugal Jordi Blanch, Barcelona Main complaint Mr M is a 30-year-old HIV+ man In
More informationHIV & Women: Neurological Issues
HIV & Women: Neurological Issues Scott Letendre, M.D. Professor of Medicine University of California, San Diego 1 Do women differ from men in their risk for neurocognitive and mood disorders? 2 As the
More informationEpilepsy and Neuropsychology
Epilepsy and Neuropsychology Dr. Sare Akdag, RPsych Neuropsychology Service, BC Children s Hospital Clinical Assistant Professor, Dept of Paediatrics, UBC November 24, 2008 BC Epilepsy Society Lecture
More informationNutrition & the healthy ageing of the brain
School of something FACULTY OF OTHER Nutrition & the healthy ageing of the brain Professor Louise Dye Chair in Nutrition and Behaviour Human Appetite Research Unit Institute of Psychological Sciences University
More informationSupplementary Online Content
Supplementary Online Content Krebs EE, Gravely A, Nugent S, et al. Effect of opioid vs non-opioid medications on pain-related function in patients with chronic back pain or hip or knee osteoarthritis pain:
More informationCopyright 2002 American Academy of Neurology. Volume 58(8) 23 April 2002 pp
Copyright 2002 American Academy of Neurology Volume 58(8) 23 April 2002 pp 1288-1290 Improved executive functioning following repetitive transcranial magnetic stimulation [Brief Communications] Moser,
More informationMethod. NeuRA Schizophrenia and bipolar disorder April 2016
Introduction Schizophrenia is characterised by positive, negative and disorganised symptoms. Positive symptoms refer to experiences additional to what would be considered normal experience, such as hallucinations
More informationBrain Imaging Applied to Memory & Learning
Brain Imaging Applied to Memory & Learning John Gabrieli Department of Brain & Cognitive Sciences Institute for Medical Engineering & Sciences McGovern Institute for Brain Sciences MIT Levels of Analysis
More informationFrontal striatal cognitive deficits in patients with chronic schizophrenia
Brain (1997), 120, 1823 1843 Frontal striatal cognitive deficits in patients with chronic schizophrenia Christos Pantelis, 1 Thomas R. E. Barnes, 2 Hazel E. Nelson, 3 Susan Tanner, 3 Lisa Weatherley, 3
More informationWorking Memory Impairments in Patients with Major Depressive Disorder
308-33 388 3 Iranian Journal of Psychiatry and Clinical Psychology, Vol. 5, No. 3, Fall 009, 308-3 Short Scientific Article Working Memory Impairments in Patients with Major Depressive Disorder Neda Nazarboland*,
More informationCHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE
CHAPTER 5 NEUROPSYCHOLOGICAL PROFILE OF ALZHEIMER S DISEASE 5.1 GENERAL BACKGROUND Neuropsychological assessment plays a crucial role in the assessment of cognitive decline in older age. In India, there
More informationInterventions on Lifestyle and Social Support Factors: Sleep Quality and Disorders
Interventions on Lifestyle and Social Support Factors: Sleep Quality and Disorders Preventing Dementia and Cognitive Impairment: A Workshop Susan M. McCurry, PhD Northwest Research Group on Aging Department
More informationOverview of the Effect of Herbal Medicines and Isoflavones on the Treatment of Cognitive Function
pissn: 2288-6478, eissn: 2288-6761 https://doi.org/10.6118/jmm.2018.24.2.113 Original Article Overview of the Effect of Herbal Medicines and Isoflavones on the Treatment of Cognitive Function Nasibeh Roozbeh
More informationWHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014
WHI Memory Study (WHIMS) Investigator Data Release Data Preparation Guide April 2014 1. Introduction This release consists of a single data set from the WHIMS Epidemiology of Cognitive Health Outcomes
More informationSTRESS AND AROUSAL CIRCADIAN RHYTHMS IN SMOKERS AND NON-SMOKERS WORKING DAY AND NIGHT SHIFTS
STRESS MEDICINE, VOL. 13: 91±97 (1997) STRESS AND AROUSAL CIRCADIAN RHYTHMS IN SMOKERS AND NON-SMOKERS WORKING DAY AND NIGHT SHIFTS M. E. E. JONES 1, Bsc AND A.C. PARROTT 1, BSc, PhD, CPsychol, FBPs S
More informationPhysiology of Menopause
6/4/18 21 Physiology of Menopause Timothy Rowe University of British Columbia 6/4/18 22 I have received consulting fees and honoraria for speaking from Pfizer Canada Inc. I have no other competing or potentially
More informationNeuropsychology of Attention Deficit Hyperactivity Disorder (ADHD)
Neuropsychology of Attention Deficit Hyperactivity Disorder (ADHD) Ronna Fried, Ed.D. Director of Neuropsychology in the Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD, Massachusetts
More informationLearning objectives 6/20/2018
Cognitive impairment of patients with chronic migraine, in a neuropsychological assessment, does not depend on the use of topiramate or comorbidities Ferreira KS, MD, PhD Professor, Neurology Clinic, Medicine
More informationPsychological factors that influence fall risk: implications for prevention
Psychological factors that influence fall risk: implications for prevention Kaarin J. Anstey Professor & Director, Ageing Research Unit, Centre for Mental Health Research Psychological perspective on Injury
More informationCognitive Testing on Mobile & Wearable Devices
Cognitive Testing on Mobile & Wearable Devices Krystyna Zaluski CANTAB Connect Prodromal Alzheimer s Background Cambridge Cognition 2016. All rights reserved Page 1 Overview A neuroscience digital health
More informationThe significance of sensory motor functions as indicators of brain dysfunction in children
Archives of Clinical Neuropsychology 18 (2003) 11 18 The significance of sensory motor functions as indicators of brain dysfunction in children Abstract Ralph M. Reitan, Deborah Wolfson Reitan Neuropsychology
More informationA concept that refers to individual differences in abilities to: Acquire knowledge Think and reason effectively Deal adaptively with the environment
Intelligence A concept that refers to individual differences in abilities to: Acquire knowledge Think and reason effectively Deal adaptively with the environment The Psychometric Approach to Intelligence
More informationNeuropsychological Evaluation of
Neuropsychological Evaluation of Alzheimer s Disease Joanne M. Hamilton, Ph.D. Shiley-Marcos Alzheimer s Disease Research Center Department of Neurosciences University of California, San Diego Establish
More informationUpdate on Falls Prevention Research
Update on Falls Prevention Research Professor Stephen Lord Coffs Harbour Falls Prevention Network Rural Forum 28 th February 2014 Acknowledgments: Dr Jasmine Menant, Mr. Daniel Schoene Recent falls risk
More informationARIC STUDY MANUSCRIPT PROPOSAL # 714. PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority:
1 ARIC STUDY MANUSCRIPT PROPOSAL # 714 PC Reviewed: 03/07/00 Status: Deferred Priority: SC Reviewed: Status: Priority: 1. a. Full Title: Effect of menopausal status on mood: The influence of demographic
More informationNutritional intervention in early Alzheimer s disease. Sasha Newsam, PhD Global Medical Affairs Manager Nutricia
Nutritional intervention in early Alzheimer s disease Sasha Newsam, PhD Global Medical Affairs Manager Nutricia Agenda Nutrition and brain function Single nutrient intervention Diet and risk of Alzheimer
More informationSupplementary Online Content
Supplementary Online Content Redlich R, Opel N, Grotegerd D, et al. Prediction of individual response to electroconvulsive therapy via machine learning on structural magnetic resonance imaging data. JAMA
More informationRandomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up
Addictive Behaviors 32 (2007) 3060 3064 Short communication Randomized controlled trial of physical activity counseling as an aid to smoking cessation: 12 month follow-up Michael Ussher a,, Robert West
More informationCognitive remediation in Recent Onset Schizophrenia: Results of an effectiveness trial
The Brain Dynamics Centre www.brain-dynamics.net Westmead Hospital & University of Sydney Cognitive remediation in Recent Onset Schizophrenia: Results of an effectiveness trial Dr Anthony Harris University
More informationAuthor's response to reviews
Author's response to reviews Title: Effects of a commercial product containing Guarana on psychological well-being, anxiety and mood: a single-blind, placebo-controlled study in heathy subjects Authors:
More informationJung Wan Kim* Department of Speech Pathology of Daegu University, Gyeongsan, South Korea
J. Ecophysiol. Occup. Hlth. 16(1&2), 2016, 32 36 2016 The Academy of Environmental Biology, India DOI : 10.15512/joeoh/2016/v16i1&2/15795 The Efficiency and Efficacy of On-Line Vs. Off-Line Cognitive Rehabilitation
More informationPRE-TREATMENT FACTORS RELATED TO COGNITIVE FUNCTIONING IN WOMEN NEWLY DIAGNOSED WITH BREAST CANCER
PSYCHO-ONCOLOGY Psycho-Oncology 14: 70 78 (2005) Published online 30 April 2004 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/pon.821 PRE-TREATMENT FACTORS RELATED TO COGNITIVE FUNCTIONING
More informationConfabulation behavior and false memories in Korsakoff s syndrome: Role of source memory and executive functioning
Psychiatry and Clinical Neurosciences 2008; 62: 220 225 doi:10.1111/j.1440-1819.2008.01758.x Regular Article Confabulation behavior and false memories in Korsakoff s syndrome: Role of source memory and
More informationSUBJECTS AND METHODS STUDY 1
INTRODUCTION Through the ages people have searched for substances and dietary supplements that affect sexual drive or desire. A number of remedies have been developed and tried. For instance the rhinoceros
More informationANNOTATED BIBLIOGRAPHY
ANNOTATED BIBLIOGRAPHY Source 1: Akpinar, B. (2005). The role of the sense of smell in learning and the effect of aroma in cognitive learning. Pakistan Journal of Social Science, 3(7), Retrieved from http://docsdrive.com/
More information